AbCellera Biologics Inc (ABCL) concluded trading on Wednesday at a closing price of $3.20, with 4.08 million shares of worth about $13.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -0.93% during that period and on January 29, 2025 the price saw a loss of about -3.03%. Currently the company’s common shares owned by public are about 295.16M shares, out of which, 221.93M shares are available for trading.
Stock saw a price change of -9.35% in past 5 days and over the past one month there was a price change of 5.61%. Year-to-date (YTD), ABCL shares are showing a performance of 9.22% which decreased to -39.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.34 but also hit the highest price of $5.62 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 3.01 million. The stock is currently trading 2.33% above its 20-day simple moving average (SMA20), while that difference is up 7.84% for SMA50 and it goes to 4.78% higher than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 295.16M outstanding shares and institutions hold larger chunk of about 34.57% of that.
The stock has a current market capitalization of $945.17M and its 3Y-monthly beta is at 0.43. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 9.34 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 6.17% while standing at 7.31% over the month.
Stock’s fiscal year EPS is expected to drop by -15.13% while it is estimated to increase by 3.35% in next year.
Coverage by The Benchmark Company stated AbCellera Biologics Inc (ABCL) stock as a Buy in their note to investors on February 22, 2024, suggesting a price target of $9 for the stock. Stock get an Overweight rating from Piper Sandler on October 13, 2023.
